vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Primis Financial Corp. (FRST). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $45.6M, roughly 1.1× Primis Financial Corp.). Primis Financial Corp. runs the higher net margin — 16.0% vs -42.0%, a 58.1% gap on every dollar of revenue. Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 13.0%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.

BCYC vs FRST — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.1× larger
BCYC
$48.0M
$45.6M
FRST
Higher net margin
FRST
FRST
58.1% more per $
FRST
16.0%
-42.0%
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
13.0%
FRST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCYC
BCYC
FRST
FRST
Revenue
$48.0M
$45.6M
Net Profit
$-20.2M
$7.3M
Gross Margin
Operating Margin
-51.5%
Net Margin
-42.0%
16.0%
Revenue YoY
1193.3%
Net Profit YoY
61.1%
200.0%
EPS (diluted)
$-0.29
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
FRST
FRST
Q1 26
$45.6M
Q4 25
$48.0M
$80.9M
Q3 25
$11.7M
$41.0M
Q2 25
$2.9M
$43.2M
Q1 25
$10.0M
$58.7M
Q4 24
$3.7M
$38.8M
Q3 24
$2.7M
$37.3M
Q2 24
$9.4M
$35.7M
Net Profit
BCYC
BCYC
FRST
FRST
Q1 26
$7.3M
Q4 25
$-20.2M
$29.5M
Q3 25
$-59.1M
$6.8M
Q2 25
$-79.0M
$2.4M
Q1 25
$-60.8M
$22.6M
Q4 24
$-26.2M
Q3 24
$-50.8M
$1.2M
Q2 24
$-39.8M
$3.4M
Operating Margin
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
-51.5%
44.8%
Q3 25
-558.6%
21.3%
Q2 25
-2965.8%
6.9%
Q1 25
-703.7%
41.9%
Q4 24
-123.0%
Q3 24
-2385.9%
-3.1%
Q2 24
-498.3%
7.8%
Net Margin
BCYC
BCYC
FRST
FRST
Q1 26
16.0%
Q4 25
-42.0%
36.5%
Q3 25
-503.7%
16.7%
Q2 25
-2703.8%
5.6%
Q1 25
-608.9%
38.6%
Q4 24
-100.3%
Q3 24
-1898.4%
3.3%
Q2 24
-425.3%
9.6%
EPS (diluted)
BCYC
BCYC
FRST
FRST
Q1 26
$0.30
Q4 25
$-0.29
$1.19
Q3 25
$-0.85
$0.28
Q2 25
$-1.14
$0.10
Q1 25
$-0.88
$0.92
Q4 24
$-0.95
Q3 24
$-0.74
$0.05
Q2 24
$-0.77
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
FRST
FRST
Cash + ST InvestmentsLiquidity on hand
$628.1M
$159.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$427.2M
Total Assets
$717.6M
$4.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
FRST
FRST
Q1 26
$159.9M
Q4 25
$628.1M
$143.6M
Q3 25
$648.3M
$63.9M
Q2 25
$721.5M
$94.1M
Q1 25
$793.0M
$57.0M
Q4 24
$879.5M
$64.5M
Q3 24
$890.9M
$77.3M
Q2 24
$961.4M
$66.6M
Total Debt
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Stockholders' Equity
BCYC
BCYC
FRST
FRST
Q1 26
$427.2M
Q4 25
$610.0M
$422.9M
Q3 25
$618.5M
$382.2M
Q2 25
$668.9M
$376.4M
Q1 25
$740.3M
$375.6M
Q4 24
$793.1M
$351.8M
Q3 24
$831.0M
$381.0M
Q2 24
$873.8M
$376.0M
Total Assets
BCYC
BCYC
FRST
FRST
Q1 26
$4.3B
Q4 25
$717.6M
$4.0B
Q3 25
$764.0M
$4.0B
Q2 25
$832.2M
$3.9B
Q1 25
$883.9M
$3.7B
Q4 24
$956.9M
$3.7B
Q3 24
$996.7M
$4.0B
Q2 24
$1.1B
$4.0B
Debt / Equity
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
FRST
FRST
Operating Cash FlowLast quarter
$-19.3M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-41.5%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
$-19.3M
$10.8M
Q3 25
$-71.2M
$-11.4M
Q2 25
$-72.8M
$-41.0M
Q1 25
$-86.4M
$34.4M
Q4 24
$-164.7M
$19.5M
Q3 24
$-39.8M
$6.1M
Q2 24
$-44.6M
$52.3M
Free Cash Flow
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
$-19.9M
$9.0M
Q3 25
$-71.8M
Q2 25
$-73.3M
Q1 25
$-87.0M
Q4 24
$-166.0M
$18.3M
Q3 24
$-40.3M
Q2 24
$-45.0M
FCF Margin
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
-41.5%
11.2%
Q3 25
-612.3%
Q2 25
-2509.7%
Q1 25
-871.7%
Q4 24
-4475.7%
47.3%
Q3 24
-1504.7%
Q2 24
-481.2%
Capex Intensity
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
1.2%
2.1%
Q3 25
5.7%
Q2 25
17.1%
Q1 25
6.1%
Q4 24
33.3%
3.1%
Q3 24
16.3%
0.0%
Q2 24
4.5%
0.0%
Cash Conversion
BCYC
BCYC
FRST
FRST
Q1 26
Q4 25
0.36×
Q3 25
-1.67×
Q2 25
-16.82×
Q1 25
1.52×
Q4 24
Q3 24
4.93×
Q2 24
15.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

FRST
FRST

Net Interest Income$32.1M70%
Noninterest Income$13.6M30%

Related Comparisons